Goals of the Collaboration Sample Clauses

Goals of the Collaboration. The goal of this collaboration is the creation of an original work for commercial exploitation.
Sample 1
AutoNDA by SimpleDocs
Goals of the Collaboration. The collaboration has the following goals, while maintaining separate and distinct brands for its identity assurance programs: • Promote the existence of this MOU to each other’s membership and participant bases; • Confirm onboarding and delisting processes with Annex 1 to this MOU • Regularly update and improve the processes and other aspects of the collaboration for IDESG self-­‐attestation and Kantara approval. • Explore the feasibility of further collaboration on activities currently outside the scope of this MOU, such as future third party assessment of IDESG’s IDEF in areas such as outsourcing to Kantara IDESG’s program governance, third party assessment, and approval scheme under IDESG’s brand.
Sample 1
Goals of the Collaboration. The Collaboration has the following goals: • To support and advance the mission through two-way exchange and transfer of knowledge and expertise; • To coordinate our efforts as thought leaders, in influencing debate and actions that advance the standardization and interoperability of identity management, security, and privacy innovation policy and technology. • KI to contribute elements of the Kantara Identity Assurance Framework (initially the Assurance Assessment Scheme and Assessor Qualifications and Requirements) to the DIACC, under terms and conditions to be agreed at a later date. • DIACC to contribute components of the Pan-Canadian Identity Trust Framework to KI, under terms and conditions to be agreed at a later date. • XX and DIACC will consider as part of the mutual contribution of documents between organizations, the grant of the right to make derivative works. • KI and the DIACC executive teams to information share for the purpose of international cross-recognition between the DIACC and KI assurance and interoperability programs as a future goal of mutual benefit
Sample 1
Goals of the Collaboration. The goals of the Collaboration, expressed herein as an intent (rather than creating any express or implied liability on the part of either Party), shall be to […***…] research and discovery of GPR119 Agonist Compounds for the treatment of Type 2 Diabetes and related metabolic diseases. It is a further goal of the Collaboration to provide to BI a Collaboration Product that is […***…] treatment of Type 2 Diabetes.
Sample 1
Goals of the Collaboration. Pursuant to this Agreement, EPIX will use Commercially Reasonable Efforts to conduct the EPIX Programs with the goal of bringing [********] from each EPIX Program to Proof of Concept and making each such Candidate Compound (together with [********] at Candidate Compound stage and all other EPIX Program Compounds) available to GSK under an exclusive license as further provided in Article 5. If GSK exercises an Option to any such EPIX Program at PoC in accordance with Section 4.1, such EPIX Program shall be further Developed and Commercialized by GSK as set forth herein. Any Licensed Product Developed and successfully Commercialized shall be marketed and sold by GSK, its Affiliates and Sublicensees, and GSK shall pay milestones and royalties to EPIX in connection therewith in accordance with Article 8. EPIX shall have an option to undertake co-promotion activities with respect to any Licensed Product that incorporates a GSK Development Compound from the 5-HT4 Partial Agonist Program as and to the extent set forth in Article 6.
Sample 1
Goals of the Collaboration. The purpose of the Collaboration is to use the Dyax Technology to advance the discovery, development and commercialization of Dyax Leads and Collaboration Leads in the Diagnostic Imaging Field which will be accomplished through Collaboration Projects that will be submitted by the parties either jointly or individually to the Steering Committee during the Research Term for consideration and approval. After the Research Term expires, the Collaboration will continue with the Collaboration Projects and Bracco may use Collaboration Projects to advance the discovery, development and commercialization of Collaboration Leads and Dyax Leads in the Diagnostic Imaging Field. To further the purpose of the Collaboration, the parties have established the following Collaboration Goals: *****
Sample 1
Goals of the Collaboration. The goals of the Collaboration, expressed herein as an intent (rather than creating any express or implied liability on the part of either Party) shall be:
Sample 1
AutoNDA by SimpleDocs
Goals of the Collaboration 
Sample 1Sample 2Sample 3See All (5)

Related to Goals of the Collaboration

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Joint Patent Rights With respect to any potentially patentable Joint Invention, the Parties shall confer and agree upon which Party, if any, shall prepare, file, Prosecute (including any interferences, reissue proceedings, and other administrational proceedings) and Maintain patent applications covering such Joint Invention (any such patent application and any patents issuing therefrom a “Joint Patent Right”), at the responsible Party’s expense. It is the intention of the Parties that, unless otherwise agreed in writing, ATI would prepare, file, Prosecute and Maintain any Joint Patent Rights. The Party that Prosecutes a patent application in the Joint Patent Rights (the “Prosecuting Party”) shall provide the other Party reasonable opportunity to review and comment on such Prosecution efforts regarding the applicable Joint Patent Rights in the particular jurisdictions, and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts. The Prosecuting Party shall provide the other Party with a copy of all material communications from any patent authority in the applicable jurisdictions regarding the Joint Patent Rights being Prosecuted by such Party, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses. In particular, each Party agrees to provide the other Party with all information necessary to enable the other Party to comply with the duty of candor/duty of disclosure requirements of any patent authority. Should ATI determine that it will no longer support the continued Prosecution or Maintenance of a particular Joint Patent Right in a country or jurisdiction, ATI shall provide Rigel with written notice of such determination at least thirty (30) Business Days prior to any deadline for taking action to avoid abandonment of such Joint Patent Right. Rigel shall have the right, but not ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 obligation, to file, Prosecute and Maintain such Joint Patent Rights in the applicable jurisdiction at Rigel’s expense.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Commercialization Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to commercialize a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries. If Novartis commercializes a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries, Novartis will be deemed to satisfy all diligence obligations with respect to such Profile.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.